Associated tags: Prostate cancer, SCNC, Rectum, Liver, Patient, Lymph, Progression-free survival, Safety, Therapy, Neoplasm, Society, CTC, Artificial intelligence, Medical imaging, FDA, RECIST, Pharmaceutical industry, Pembrolizumab, HAVEN, De novo, Trial of the century, BID, ASCO
Retrieved on:
Monday, February 13, 2023
Physician,
Clinical Science (journal),
ASCO,
BID,
Trial of the century,
SCNC,
Aes,
De novo,
University of California, San Francisco,
Event,
Pembrolizumab,
Șaeș,
Safety,
RECIST,
Phenotype,
Patient,
Incidence,
DPP9,
Artificial intelligence,
AE,
University,
Prostate cancer,
Neoplasm,
Therapy,
Associate,
Poster,
Disease,
FDA,
Progression-free survival,
PR,
Society,
CTC,
Publication,
UCSF,
Medical imaging,
Pharmaceutical industry,
Vaccine,
HAVEN,
Medicine NEW HAVEN, Conn., Feb. 13, 2023 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology, today announced full data from its Phase 2a trial of BXCL701, the Company's investigational, oral innate immune activator, in combination with KEYTRUDA® (pembrolizumab) in small cell neuroendocrine (SCNC) variant metastatic castration-resistant prostate cancer (mCRPC) patients after at least one prior line of chemotherapy for locally advanced or metastatic prostate cancer. Results will be presented in a rapid abstract presentation and a poster presentation at the 2023 American Society of Clinical Oncology Genitourinary Cancers (ASCO GU) Symposium on February 16, 2023.
Key Points:
- Results will be presented in a rapid abstract presentation and a poster presentation at the 2023 American Society of Clinical Oncology Genitourinary Cancers (ASCO GU) Symposium on February 16, 2023.
- In patients with RECIST 1.1-defined measurable disease (n = 25), partial response (PR) was observed in 5 (20%) patients (4 confirmed PR, 1 unconfirmed PR).
- In 2022, there were an estimated 268,5001 new prostate cancer patients in the United States, with approximately 10,740 patients progressing to SCNC.
- The Phase 2a trial is an open-label, multicenter study to evaluate the safety and efficacy of BXCL701 in combination with pembrolizumab in men with SCNC.
Retrieved on:
Wednesday, January 11, 2023
De novo,
SCNC,
Prostate cancer,
ASCO,
Therapy,
RECIST,
Trial of the century,
Safety,
FDA,
Neoplasm,
Artificial intelligence,
Patient,
Cancer,
CTC,
Society,
Progression-free survival,
BID,
Pembrolizumab,
Medical imaging,
Pharmaceutical industry,
HAVEN NEW HAVEN, Conn., Jan. 11, 2023 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology, today announced promising top-line data from its Phase 2 trial of BXCL701, the Company's investigational, oral innate immune activator, in combination with KEYTRUDA® (pembrolizumab) in small cell neuroendocrine metastatic castration-resistant prostate cancer (SCNC) patients. Full data have been submitted to the 2023 American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU).
Key Points:
- Full data have been submitted to the 2023 American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU).
- In 2022, there were an estimated 268,5001 new prostate cancer patients, with approximately 10,740 patients progressing to SCNC.
- The Phase 2a trial is an open-label, multicenter study to evaluate the safety and efficacy of BXCL701 in combination with pembrolizumab in men with SCNC.
- The primary endpoint of the trial is a composite response rate defined as RECIST 1.1 and/or PSA50 and/or CTC count conversion.
